Buy Sotalol powder (3930-20-9) hplc≥98% – β-Agonist Wisepowder
Chemical Base Information
Chemical name N-(4-(1-Hydroxy-2-(isopropylamino)ethyl)phenyl)methanesulfonamide
Synonyms 4′-(1-hydroxy-2-(isopropylamino)ethyl)methane, sulfonanilide, Sotalol, Sotalolo, Sotalolum,β-cardone
Molecular Formula C12H20N2O3S
Molecular Weight 272.363 g/mol
Melting Point 206.5-207 °C
InChI Key ZBMZVLHSJCTVON-UHFFFAOYSA-N
Appearance white to off-white
Half Life 10-20 hours
Solubility Soluble (5510 mg/L)
Storage Condition tore sotalol at 77°F (25°C). You can store it for a short time in temperatures as low as 59°F (15°C) and as high as 86°F (30°C).
Application Sotalol is a medication used to treat and prevent abnormal heart rhythms
Testing Document Available
03 Sotalol (3930-20-9) General Description
Sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter.Label There are also oral solutions and intravenous injections indicated for patients requiring sotalol, but for whom a tablet would not be appropriate.
Sotalol is a competitive inhibitor of the rapid potassium channel. This inhibition lengthens the duration of action potentials and the refractory period in the atria and ventricles. The inhibition of rapid potassium channels is increases as heart rate decreases, which is why adverse effects like torsades de points is more likely to be seen at lower heart rates.6 L-sotalol also has beta adrenergic receptor blocking activity seen above plasma concentrations of 800ng/L. The beta blocking ability of sotalol further prolongs action potentials. D-sotalol does not have beta blocking activity but also reduces a patient’s heart rate while standing or exercising. These actions combine to produce a negative inotropic effect that reduces the strength of contractility of muscle cells in the heart. Extension of the QT interval is also adversely associated with the induction of arrhythmia in patients.
04 Sotalol (3930-20-9) History
Sotalol was first synthesized in 1960 by A. A. Larsen of Mead-Johnson Pharmaceutical. It was originally recognized for its blood pressure lowering effects and its ability to reduce the symptoms of angina. It was made available in the United Kingdom and France in 1974, Germany in 1975, and Sweden in 1979. It became widely used in the 1980s. In the 1980s, its antiarrhythmic properties were discovered. The United States approved the drug in 1992.